Symbols

TLSI

TriSalus Life·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 3

Consensus Rating "Strong Buy"

MACD Death Cross

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TLSI

Trisalus Life Sciences, Inc.

An immunotherapy company that develops and commercialises therapies using a three-pronged therapeutic approach combining immunomodulation therapy, tumour-killing agents, and a proprietary intravascular regional delivery technology for the treatment of liver and pancreatic tumours

Industry

Life Science Tools and Services

Established Date

Listing Date

02/08/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

110

Fiscal Year Ends

12-31

Website

www.trisaluslifesci.com

Security Type

Common stock

Office address

6272 W. 91st Ave. , Westminster, Colorado 80031

Business

Introduction

TriSalus Life Sciences, Inc., a Delaware corporation, was founded in 2009. They are engaged in the research, development and sales of innovative drug delivery technologies and immuno-oncology therapies to improve the treatment of hard-to-treat liver and pancreatic cancers. Their techniques are used to provide treatment and are administered by interventional radiologists. They are developing and marketing two product lines — the Pressure Drug Delivery System (PEDD), which is currently in use, and an investigational drug, SD-101, which has shown potential to enhance the immune system response in the treatment of hepatocellular carcinoma, pancreatic cancer and other solid tumors of the liver. Their PEDD with SmartValve is the only technology that works in sync with the cardiac cycle, opening collapsed blood vessels within the tumor to achieve deeper perfusion and improve delivery of therapeutic drugs in the case of high pressure within the tumor. PEDD and SmartValve have been shown to improve treatment uptake and tumor response in prospective and retrospective clinical studies and multiple preclinical models.

Earnings Call

Q1/2025

Estimate EPS-0.2

Actual EPS-0.39

Estimate Revenue9.04M

Actual Revenue9.17M

TriSalus Life Sciences Q1 2025: Unpacking Key Contradictions on TriNav Usage, Mapping Code Impact, and Partnership Strategies

May 02,2025 07:28·
Earnings Decrypt

Q2/2025

Estimate EPS-0.22

Actual EPS-0.27

Estimate Revenue10.69M

Actual Revenue11.21M

TriSalus Life Sciences Q2 2025: Key Contradictions in Nelitolimod Strategy and TriNav Sales Projections

Aug 12,2025 10:12·
Earnings Decrypt

Company Financials

EPS

TLSI has released its 2025 Q3 earnings. EPS was reported at -0.96, versus the expected -0.17, missing expectations. The chart below visualizes how TLSI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TLSI has released its 2025 Q3 earnings report, with revenue of 11.57M, reflecting a YoY change of 57.38%, and net profit of -10.81M, showing a YoY change of -350.65%. The Sankey diagram below clearly presents TLSI's revenue sources and cost distribution.